[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$bms
$bms sees positive sentiment with FDA approval, but faces economic headwinds. Social media engagement is down, indicating potential price instability ahead.
About $bms
Analysis of social media activity related to the stock ticker $bms, likely a pharmaceutical company.
Insights #
- $bms engagements is up XXXXXX% from the previous week.
Engagements: XX #
Engagements 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXX
1 Week: XXXXX +495%
1 Month: XXXXX -XX%
1-Year High: XXXXX on 2025-08-24
1-Year Low: X on 2025-06-27
| Social Network | X | |
|---|---|---|
| Engagements | X | XX |
Mentions: X #
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
1-Year High: XX on 2025-07-21
1-Year Low: X on 2025-06-23
| Social Network | X | |
|---|---|---|
| Mentions | X | X |
Creators: X #
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $bms in the last XX hours which is up XX% from X in the previous XX hours
Daily Average: X
1 Month: X -XX%
1-Year High: XX on 2025-08-30
1-Year Low: X on 2025-04-30
Top assets mentioned In the posts about $bms in the last XX hours
Merck & Co., Inc. (MRK) Bristol-Myers Squibb Co (BMY) Ionis Pharmaceuticals, Inc. Common Stock (IONS) Sanofi (SNY)
Top topics mentioned In the posts about $bms in the last XX hours
stocks healthcare, combo, $mrk, $nwbo, $bmy, investment, $evtc, $evtde, h1, loaded, derived, $ions, $kardigan, $254m, sanofi
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$NWBO Anthony Wang gave a presentation on early findings of the trial on using DCs loaded with peptides derived from H3 G34 to treat DHG. Systemic oligoclonal anti-tumor cytotoxic T cell response was observed in the trial. Recall what happened to the combo trial after keytruda was added to the combination of DCVax-L plus poly-iclc. No doubt adding two checking point inhibitors Nivolumab and Ipilimumab to the current combination in treating DHG should deliver blockbuster results. Clearly Merck would not let this trial proceed. A systemic oligoclonal anti-tumor cytotoxic T cell response is a"
X Link @d_stock07734 2025-10-14T02:34Z XXX followers, 3613 engagements
"The Disappearing Combo How a withdrawn trial at #UCLA revealed the quiet architecture connecting $BMS $MRK and $NWBO and the people who taught the immune system to remember Prologue The Vanished Trial The notice appeared without ceremony. A single line on described a new study at UCLAs Jonsson Comprehensive Cancer Center. Patients with lethal brain tumors would receive two of Bristol Myers Squibbs most famous checkpoint inhibitorsYervoy (ipilimumab) and Opdivo (nivolumab)alongside a dendritic-cell vaccine made from their own tumors. It was small careful and quietly revolutionary: acceleration"
X Link @andrewcaravello 2025-10-14T02:03Z 1266 followers, 4091 engagements
"$EVTC $BMS Evotec SE H1 2025 revenues fall XXX% to 371.2M reiterates full-year guidance"
X Link @byul_finance 2025-08-13T11:20Z XXX followers, XXX engagements
"stockAday: Bristol Myers Squibb is a pharma dinosaur no more ($BMS)"
Reddit Link @shane_stockflare 2024-11-15T00:19Z X followers, XX engagements